The Oncology Shot with Timothee Olivier
Timothée Olivier, Alyson Haslam, Sahar van Waalwijk, Christopher Rios, Hans WestgeestMy Personal Substack
| Platform |  | Pricing | Only free issues | Publishes | Twice weekly |
|---|---|---|---|---|---|
| Issues | 31 | Founded | 8 months ago | Last Issue | 7 days ago |
| Active | |||||
Read this Newsletter
theoncologyshot.comLatest Issues
Additional Insights Into Early Daraxonrasib Data
Daraxonrasib is making headlines. A few weeks ago, a press release reported positive phase 3 results from the RASolute 302 trial in second-line metastatic pancreatic cancer, with particular emphasis on a secondary endpoint: overall survival...
World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial
Imagine you have pain. You would probably start with a single painkiller rather than immediately buying and taking a combination of different painkillers. Combining drugs may increase side effects. Besides, why spend more money if one medic...
RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?
On April 13, 2026, the company Revolution Medicines announced the positive results of the phase 3 trial RASolute 302 in pancreatic cancer via a press-release (here). The trial was a multicenter global phase 3 trial, conducted in the US, Fra...
An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.
Our new paper, with and , is out in the Journal of Cancer Policy and is openly available here! Not all patients with Smoldering Myeloma will progress to Multiple Myeloma, a malignant condition. Since many years, we knew that daratumumab (o...
The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.
The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse. They use a set of criteria called PASKWIL to define what is clinically meaningful. Recently, the Dutch have been quite excited about serplulimab, an imm...
Audience Metrics
Subscribers, engagement, traffic and sponsorship for The Oncology Shot with Timothee Olivier.
| Subscribers | Engagement | 73 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Chart Rankings
How this newsletter ranks in the official Substack charts.
| #109 |
Authors
The writers behind this newsletter.
Swiss oncologist at Geneva University Hospital. Research on trial methodology, health policy, and critical appraisal. I joined Vinay Prasad’s research lab in November 2021. Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.
Health policy researcher at UCSF
Pharmacist Medicine & Society (PharmD-PhD), National Funder’s Committee for Evaluation of Specialised Medicines and Companion Diagnostics, CZ. Associate Professor of Medical Oncology and Accessibility of Medicine, LUMC, NL
UCSF medical student, Harvard alum. Before med school, I worked in gene-editing research and industry-academic collaborations. Now focused on high-value care and healthcare policy. How do we pay for increasingly expensive therapies and innovations?
Hans Westgeest (1980) works as medical oncologist in Amphia hospital in Breda, the Netherlands. His expertise is in urogenital oncology and melanoma.
Frequently Asked Questions
How can I access the email archive for The Oncology Shot with Timothee Olivier?
You can find recent issues that have been published by The Oncology Shot with Timothee Olivier on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Oncology Shot with Timothee Olivier have?
To see how many people subscribe to The Oncology Shot with Timothee Olivier, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Oncology Shot with Timothee Olivier?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Oncology Shot with Timothee Olivier as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Oncology Shot with Timothee Olivier?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Oncology Shot with Timothee Olivier using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to The Oncology Shot with Timothee Olivier?
Scroll up to where it says Related Newsletters to see other publications like The Oncology Shot with Timothee Olivier. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Oncology Shot with Timothee Olivier?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.